Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational Study of Dermatologic Events Associated With Enfortumab Vedotin in Urothelial Carcinoma
jRCT1050230125Completed
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of enfortumab vedotin in transitional cell carcinoma (TCC), sponsored by none. Primary endpoint: Dermatologic event characteristics after enfortumab vedotin. Started Nov 2023; status: completed.
02
Drugs
enfortumab vedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT1050230125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050230125.